101080-03-9

Usage

Uses

Used in Organic Synthesis:
1-Chloro-4-Methoxy-2-Methyl-5-nitro-benzene is used as a building block in the synthesis of various organic compounds due to its reactivity and versatility.
Used in Pharmaceutical Production:
1-Chloro-4-Methoxy-2-Methyl-5-nitro-benzene is used as an intermediate for the production of pharmaceuticals, contributing to the development of new drugs.
Used in Dye Manufacturing:
1-Chloro-4-Methoxy-2-Methyl-5-nitro-benzene is utilized in the production of dyes, where its chemical properties are harnessed to create a range of colorants for various applications.
Used in Specialty Chemicals Production:
1-Chloro-4-Methoxy-2-Methyl-5-nitro-benzene is employed in the synthesis of specialty chemicals, which are used in specific industries for their unique properties.
Used in Medicinal Chemistry and Pharmacology Research:
Due to its structural features, 1-Chloro-4-Methoxy-2-Methyl-5-nitro-benzene may have potential applications in the field of medicinal chemistry and pharmacology, where it can be explored for its possible biological activities and therapeutic uses.
It is important to handle 1-Chloro-4-Methoxy-2-Methyl-5-nitro-benzene with caution, as it may pose health hazards and environmental risks if not managed properly.

Upstream product

• 7147-89-9 4-chloro-5-methyl-2-nitrophenol 
• 77-78-1 dimethyl sulfate 
• 74-88-4 methyl iodide 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 67-68-5 dimethyl sulfoxide 
• 6815-42-5 4-chloro-3-methyl-2-nitrophenol 
• 186581-53-3 diazomethane 

Downstream Products

• 101581-13-9 2-chloro-5-methoxy-4-nitrobenzoic acid 
• 1356016-29-9 2-chloro-5-methoxy-4-nitro-N-phenyl-benzamide 
• 1001347-19-8 4-amino-2-chloro-5-methoxybenzoic acid 
• 82128-70-9 5-chloro-2-methoxy-4-methylbenzaldehyde 
• 1380308-20-2 1-bromomethyl-2-chloro-5-methoxy-4-nitro-benzene 
• 1356016-30-2 4-amino-2-chloro-5-methoxy-N-phenylbenzamide 
• 1360616-09-6 (2-chloro-5-methoxy-4-nitro-phenyl)-methanol 
• 1349744-88-2 methyl 2-chloro-5-methoxy-4-nitrobenzoate 
• 886981-69-7 1-(5-chloro-4-formyl-2-methoxy-phenyl)-3-(5-cyano-pyrazin-2-yl)-urea 
• 886981-66-4 N-(4-bromomethyl-5-chloro-2-methoxy-phenyl)-2,2,2-trifluoro-acetamide 
• 886981-67-5 N-(5-chloro-4-formyl-2-methoxy-phenyl)-2,2,2-trifluoro-acetamide 
• 886981-68-6 4-amino-2-chloro-5-methoxy-benzaldehyde 
• 569688-67-1 5-chloro-2-methoxy-4-methylphenylamine 

Relevant academic research and scientific papers

ISOINDOLINONE COMPOUNDS

Disclosed herein is a compound or pharmaceutically acceptable salts or stereoisomers thereof of of formula I wherein X1 is linear or branched C1-6 alkyl, C3-6 cycloalkyl, -C1-6 alkyl C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C1-6 alkyl C6-10 aryl, C1-6 alkyl 5-10 membered heteroaryl, wherein X1 is unsubstituted or substituted with one or more of halogen, linear or branched C1-6 alkyl, linear or branched C1-6 heteroalkyl, CF3, CHF2, -O-CHF2, -O-(CH2)2-OMe, OCF3, C1-6 alkylamino, -CN, -N(H)C(O)-C1- 6alkyl, -OC(O)-C1-6alkyl, -OC(O)-C1-4alkylamino, -C(O)O-C1-6alkyl, -COOH, - CHO, -C1-6alkylC(O)OH, -C1-6alkylC(O)O-C1-6alkyl, NH2, C1-6 alkoxy or C1-6 alkylhydroxy; X2 is hydrogen, C6-10 aryl, 5-10 membered heteroaryl, -O-(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C1-4 alkyl 4-8 membered heterocycloalkyl, -O-(4-8 membered heterocycloalkyl), -O-C1-4 alkyl-(4-8 membered heterocycloalkyl), -OC(O)-C1-4alkyl-4-8 membered heterocycloalkyl or C6 aryloxy, wherein X2 is unsubstituted or substituted with one or more of linear or branched C1-6 alkyl, NH2, NMe2 or 5-6 membered heterocycloalkyl; n is 0, 1 or 2.

NEW SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS

The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF- KB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS

The invention relates to indole carboxamide derivatives of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and n are as defined in the description, their preparation and their use as pharmaceutically active compounds.

PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS

Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.

PHARMACEUTICAL COMPOUNDS

The invention provides a compound of the formula (1): or a salt, N-oxide or tautomer thereof; wherein R1 is cyano or C1-4 alkyl; R2 is hydrogen or C1-4 alkyl; R3 is hydrogen or C1-4 alkyl; R4 and R5 are the same or different and each is selected from hydrogen, saturated C1-4 hydrocarbyl and saturated C1-4 hydrocarbyloxy; R6 and R7 are the same or different and each is selected from hydrogen, halogen, CN, C1-4 alkyl and C1-4 alkoxy wherein the C1-4 alkyl and C1-4 alkoxy are each optionally substituted with hydroxy, C1-2 alkoxy or by one or more flourine atoms; R8 is hydrogen or C1-4 alkyl; Q is an alkylene chain of 1 to 4 carbon atoms in length between the moiety Ar and the nitrogen atom N, wherein one or more of the 1 to 4 carbon atoms of the alkylene chain may optionally be substituted with one or two C1-4 alkyl groups, or wherein one carbon atom of the 1 to 4 carbon atoms of the alkylene chain may optionally be substituted with a group -CH2CH2- which together with the said one carbon atom forms a cyclopropyl group; m is 1, 2, 3 or 4; n is 0 or 1; and Ar is a monocyclic or bicyclic aryl or heteroaryl group of 5 to 10 ring members containing 0, 1, 2, 3 or 4 heteroatom ring members selected from O, N and S, the aryl or heteroaryl group being optionally substituted with one to four substituents R13 as defined in the claims. The compounds are inhibitors of Chk-1 kinase and are active against cancers.

Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors

Based on the X-ray crystallography of our lead compound 1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-cyanopyrazin-2-yl)urea in the checkpoint kinase 1 (Chk1) enzyme, we modified R4, and to a lesser extent, R2, and R5 of the phenyl ring, and made a variety of N-aryl-N′-pyrazinylurea Chk1 inhibitors. Enzymatic activity less than 20 nM was observed in 15 of 41 compounds. Compound 8i provided the best overall results in the cellular assays as it abrogated doxorubicin-induced cell cycle arrest (IC50 = 1.7 μM) and enhanced doxorubicin cytotoxicity (IC50 = 0.44 μM) while displaying no single agent activity.

SEMICARBAZIDE DERIVATIVES AS KINASE INHIBITORS

The present invention relates to semicarbazide derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

Chemoselective O-methylation of phenols under non-aqueous condition

Chemoselective O-methylation of substituted phenols takes place in dry. tetrahydrofuran (THF) in the presence of LiOH.H2O and dimethylsulfate (DMS). Quantitative methyl transfer from DMS preserves the atom economy.